For the fiscal year ending December 2025, consolidated revenue was JPY 2,468.892 billion (6.0% YoY increase), operating income was JPY 479.375 billion (48.2% YoY increase), and net income attributable to owners of parent was JPY 363.150 billion (5.8% YoY increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4578","jir_company_name":"Otsuka Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4578-20260213-01.pdf","jir_short_summary":"For the fiscal year ending December 2025, consolidated revenue was JPY 2,468.892 billion (6.0% YoY increase), operating income was JPY 479.375 billion (48.2% YoY increase), and net income attributable to owners of parent was JPY 363.150 billion (5.8% YoY increase).","jir_summary":"### Performance Overview\nFor the fiscal year ending December 2025, consolidated revenue totaled JPY 2,468.892 billion (6.0% YoY increase), driven by increased sales of the antipsychotic 'Rexulti', anti-cancer agent 'Lonsurf', and the extended-release injection 'Abilify' series in the medical-related segment. Business profit was JPY 446.129 billion (3.6% YoY increase), and operating income increased significantly to JPY 479.375 billion (48.2% YoY increase). The rise in operating income was due not only to higher business profit but also to gains on the sale of shares in MicroPort Scientific Corporation and a substantial reduction in impairment losses. Net income attributable to owners of parent was JPY 363.150 billion (5.8% YoY increase). Research and development expenses were JPY 352.838 billion (12.3% YoY increase), reflecting increased investments in the development of new antipsychotic drugs and non-small cell lung cancer treatments.\n\n### Segment Performance and Future Outlook\nRevenue in the medical-related segment amounted to JPY 1,744.234 billion (7.1% YoY increase), with business profit of JPY 402.016 billion (2.9% YoY increase). The nutraceuticals-related segment recorded revenue of JPY 577.669 billion (3.7% YoY increase), and business profit of JPY 68.970 billion (7.4% YoY increase), maintaining steady growth. The consumer-related segment posted revenue of JPY 34.634 billion (2.6% YoY increase) and business profit of JPY 25.171 billion (6.4% YoY increase). For the fiscal year ending December 2026, revenue is projected at JPY 2,520 billion (2.1% YoY increase), while business profit is forecasted to decline to JPY 355 billion (20.4% YoY decrease), primarily due to the impact of generic drugs in the medical-related segment and aggressive investments in growth products. Annual dividends are expected to remain at 140 JPY.","jir_financial_highlights":"Revenue: 2,468,892 million JPY (6.0% YoY increase)\nBusiness Profit: 446,129 million JPY (3.6% YoY increase)\nOperating Income: 479,375 million JPY (48.2% YoY increase)\nNet Income Attributable to Owners of Parent: 363,150 million JPY (5.8% YoY increase)\nResearch and Development Expenses: 352,838 million JPY (12.3% YoY increase)\nDividends (Annual): 140.00 JPY (16.7% YoY increase (120 JPY \u2192 140 JPY))\nNumber of Shares Outstanding (End of Period): 542,988,917 shares (Decrease YoY (552,024,717 shares \u2192 542,988,917 shares))","jir_category":"","jir_hashtags":"#OtsukaHoldings, #FinancialSummary, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: 2,468,892 million JPY (6.0% YoY increase)\nOperating Income: 479,375 million JPY (48.2% YoY increase)\nNet Income Attributable to Owners of Parent: 363,150 million JPY (5.8% YoY increase)","jir_meta_title":"Otsuka Holdings Financial Summary for Fiscal Year Ending December 2025 - Revenue Up 6.0%, Operating Income Up 48.2%","jir_meta_description":"Otsuka Holdings Co., Ltd.'s financial summary for the fiscal year ending December 2025 reports consolidated revenue of JPY 2,468.892 billion (6.0% YoY increase), operating income of JPY 479.375 billion (48.2% YoY increase), and net income attributable to owners of parent of JPY 363.150 billion (5.8% YoY increase).","jir_og_title":"Otsuka Holdings Announces Financial Summary for Fiscal Year Ending December 2025","jir_og_description":"Otsuka Holdings' financial summary for the fiscal year ending December 2025 shows increases in revenue and operating income, with plans to raise dividends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Fiscal Year Ending December 2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[2329861,2468892,2520000],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Fiscal Year Ending December 2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[323564,479375,360000],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Fiscal Year Ending December 2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income Attributable to Owners of Parent\\\",\\\"data\\\":[343120,363150,265000],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown (Fiscal Year Ending December 2025 Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Medical-Related Business\\\",\\\"Nutraceutical-Related Business\\\",\\\"Consumer-Related Business\\\",\\\"Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1744234,577669,34634,115922],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\",\\\"#6c757d\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"r_and_d_expense_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Research and Development Expense Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Fiscal Year Ending December 2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Research and Development Expenses\\\",\\\"data\\\":[314233,352838,378000],\\\"borderColor\\\":\\\"#17a2b8\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6875,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-28951","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n